Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Beluga Health vs NuuVim

Beluga Health
Graded #431

Lower grade

vs+15.299999999999997
NuuVim
Graded #101

Higher grade

The verdict

NuuVim takes it — 71.1/100 to 55.8/100.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +52
45
97
Dose & formulationNuuVim +56
40
96
Clinical oversightBeluga Health +34
76
42
Labs & monitoringBeluga Health +12
62
50
FulfillmentBeluga Health +3
64
61
Contract termsEven
55
55
Beluga Health · left barNuuVim · right bar

The numbers

MetricBeluga HealthNuuVim
WeighScore55.8/10071.1/100
GradeCC
Scorecard rank#431#101
SemaglutideNot disclosed$79/mo (all doses, compounded)
TirzepatideNot disclosed$133/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Beluga Health

Graded #431 · C

Strengths

  • Supports GLP-1 care with compounded semaglutide and tirzepatide
  • Board-certified providers and a 50-state medical infrastructure
  • LegitScript certified with SOC 2 and ISO 27001 security
  • Pharmacies follow FDA/USP standards with third-party batch testing
  • Powers many DTC brands as a turnkey telehealth backbone

Where it loses points

  • White-label B2B group, not a direct consumer-facing service
  • Offers compounded, not FDA-approved branded, GLP-1s
  • No public consumer pricing for the GLP-1 offering
  • Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
  • Care quality varies by the consumer brand using the platform
NuuVim

Graded #101 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • No founder, CEO, medical director, or pharmacist-in-charge named
  • Refund and cancellation policy not surfaced on the site
  • Compounded medications are not FDA-approved
  • Doesn't disclose which pharmacy fills which drug or form
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard